Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478202 | 0.97 | MEN1 (0.50) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL4474592 | 0.84 | MEN1 (0.51) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL6382366 | 0.83 | MEN1 (0.58) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL4486547 | 0.83 | MEN1 (0.58) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL6383663 | 0.82 | MEN1 (0.53) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL6383871 | 0.81 | HDAC1 (0.53) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL6384740 | 0.80 | HDAC1 (0.54) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL1063809 | 0.80 | HDAC1 (0.65) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL4469281 | 0.80 | MEN1 (0.56) | MEN1AHRKMT2AHDAC1P4HTM | |
| SCHEMBL6382408 | 0.80 | MEN1 (0.56) | MEN1AHRKMT2AHDAC1P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071219-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | claimed |
| EP-1592667-A2 | NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069803-A2 | MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | claimed |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | claimed |
| US-7501451-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7071219-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | FERTIG GEORG | 2006-04-27 | — | — | US | disclosed |
| EP-1592667-A2 | NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069803-A2 | MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC10, HDAC11 | MEN1 1320/4885AHR 332/4885KMT2A 24/4885 |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC11, HDAC10 | MEN1 1210/4885AHR 231/4885KMT2A 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.